- Home
- STT vs INSM Comparison
STT vs INSM Comparison
Compare STT & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STT
- INSM
- Stock Information
- Founded
- STT 1792
- INSM 1988
- Country
- STT United States
- INSM United States
- Employees
- STT N/A
- INSM N/A
- Industry
- STT Major Banks
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- STT Finance
- INSM Health Care
- Exchange
- STT Nasdaq
- INSM Nasdaq
- Market Cap
- STT 32.3B
- INSM 29.0B
- IPO Year
- STT N/A
- INSM 2000
- Fundamental
- Price
- STT $116.61
- INSM $186.37
- Analyst Decision
- STT Buy
- INSM Strong Buy
- Analyst Count
- STT 13
- INSM 19
- Target Price
- STT $127.92
- INSM $171.12
- AVG Volume (30 Days)
- STT 2.4M
- INSM 2.1M
- Earning Date
- STT 10-17-2025
- INSM 10-30-2025
- Dividend Yield
- STT 2.88%
- INSM N/A
- EPS Growth
- STT 49.61
- INSM N/A
- EPS
- STT 9.43
- INSM N/A
- Revenue
- STT $13,626,000,000.00
- INSM $447,022,000.00
- Revenue This Year
- STT $7.99
- INSM $32.08
- Revenue Next Year
- STT $4.63
- INSM $125.86
- P/E Ratio
- STT $12.37
- INSM N/A
- Revenue Growth
- STT 8.59
- INSM 30.34
- 52 Week Low
- STT $72.81
- INSM $60.40
- 52 Week High
- STT $119.33
- INSM $197.08
- Technical
- Relative Strength Index (RSI)
- STT 53.73
- INSM 72.17
- Support Level
- STT $113.83
- INSM $154.79
- Resistance Level
- STT $119.33
- INSM $197.08
- Average True Range (ATR)
- STT 2.85
- INSM 6.93
- MACD
- STT 0.06
- INSM 1.93
- Stochastic Oscillator
- STT 81.49
- INSM 74.67
About STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $49 trillion in assets under custody and administration, and $5.1 trillion in assets under management, as of June 30, 2025, State Street operates globally in more than 100 geographic markets and employs about 53,000 worldwide.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.